Run M1 CRC Challenge Assessment (SAMPLE 1)

Your name will be kept confidential to participants and any feedback you provide as an assessor will be forwarded anonymously.

Patient TC is a 52 year old, previously healthy woman who has presented to the emergency room with a perforated colon adenocarcinoma and evidence of distant metastases.  She has been treated with a right hemicolectomy, and is now being assessed by medical oncology for further management.  The case is being referred for biomarker testing.

DOB: Feb 7 1970 MRN: 12345

Lab 902 SAMPLE 1

REFERENCE RESULTS: MSI-High (MMR-deficient), KRAS G13D
Yes
No
Hereditary cancer follow-up
Yes
No
Sensitivity to immune checkpoint inhibitors
Yes
No
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No

Lab 903 SAMPLE 1

REFERENCE RESULTS: MSI-High (MMR-deficient), KRAS G13D
Yes
No
Hereditary cancer follow-up
Yes
No
Sensitivity to immune checkpoint inhibitors
Yes
No
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No

Lab 904 SAMPLE 1

REFERENCE RESULTS: MSI-High (MMR-deficient), KRAS G13D
Yes
No
Hereditary cancer follow-up
Yes
No
Sensitivity to immune checkpoint inhibitors
Yes
No
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No

Lab 905 SAMPLE 1

REFERENCE RESULTS: MSI-High (MMR-deficient), KRAS G13D
Yes
No
Hereditary cancer follow-up
Yes
No
Sensitivity to immune checkpoint inhibitors
Yes
No
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No

Lab 906 SAMPLE 1

REFERENCE RESULTS: MSI-High (MMR-deficient), KRAS G13D
Yes
No
Hereditary cancer follow-up
Yes
No
Sensitivity to immune checkpoint inhibitors
Yes
No
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No

Lab 907 SAMPLE 1

REFERENCE RESULTS: MSI-High (MMR-deficient), KRAS G13D
Yes
No
Hereditary cancer follow-up
Yes
No
Sensitivity to immune checkpoint inhibitors
Yes
No
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No

Lab 908 SAMPLE 1

REFERENCE RESULTS: MSI-High (MMR-deficient), KRAS G13D
Yes
No
Hereditary cancer follow-up
Yes
No
Sensitivity to immune checkpoint inhibitors
Yes
No
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No

Lab 901 SAMPLE 1

Results were not submitted in time for assessment. Complete the questions below to the best of your abilities.

REFERENCE RESULTS: MSI-High (MMR-deficient), KRAS G13D
Yes
No
N/A
Hereditary cancer follow-up
Yes
No
N/A
Sensitivity to immune checkpoint inhibitors
Yes
No
N/A
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No
N/A